Gemcitabine triggers a pro-survival response in pancreatic cancer cells through activation of the MNK2/eIF4E pathway

Oncogene

Volumn 32, Issue 23, 2013, Pages 2848-2857

  Adesso, L ^a,b   Calabretta, S ^a,b   Barbagallo, F ^a,c   Capurso, G ^b   Pilozzi, E ^b   Geremia, R ^a   Delle Fave, G ^a,b   Sette, C ^a,c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

drug resistance; eIF4E phosphorylation; MNK2 alternative splicing

Indexed keywords

GEMCITABINE; INITIATION FACTOR 4A;

APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL SURVIVAL; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ENZYME INHIBITORS; EUKARYOTIC INITIATION FACTOR-4E; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; ISOENZYMES; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NUCLEAR PROTEINS; PANCREATIC NEOPLASMS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN-SERINE-THREONINE KINASES; RNA SPLICING; RNA-BINDING PROTEINS; SIGNAL TRANSDUCTION;

EID: 84879415211     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.306     Document Type: Article

References (32)

1. Kern SE, Shi C, Hruban RH. The complexity of pancreatic ductal cancers and multidimensional strategies for therapeutic targeting. J Pathol 2011; 223: 295-306.
2. Falasca M, Selvaggi F, Buus R, Sulpizio S, Edling CE. Targeting phosphoinositide 3-kinase pathways in pancreatic cancer-from molecular signaling to clinical trials. Anticancer Agents Med Chem 2011; 11: 455-463.
3. Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H et al. Activation of Akt and eIF4E survival pathways by rapamycin mediated mammalian target of rapamycin inhibition. Cancer Res 2005; 65: 7052-7058.
4. Wang X, Yue P, Chan C, Ye K, Ueda T, Watanabe-Fukunaga R et al. Inhibition of Mammalian Target of Rapamycin Induces Phosphatidylinositol 3-Kinase Dependent and Mnk-Mediated Eukaryotic Translation Initiation Factor 4E Phosphoryla-tion. Mol Cell Biol 2007; 27: 7405-7413.
5. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011; 12: 21-35.
6. Culjkovic B, Topisirovic I, Skrabanek L, Ruiz-Gutierrez M, Borden KL. eIF4E promotes nuclear export of cyclin D1 mRNAs via an element in the 3 UTR. J Cell Biol 2005; 169: 245-256.
7. Mamane Y, Petroulakis E, Rong L, Yoshida K, Ler LW, Sonenberg N. eIF4E-from translation to transformation. Oncogene 2004; 23: 3172-3179.
8. Ueda T, Watanabe-Fukunaga R, Fukuyama H, Fukuyama H, Nagata S, Fukunaga R. Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development. Mol Cell Biol 2004; 24: 6539-6654.
9. Buxade M, Parra-Palau JL, Proud CG. The Mnks: MAP kinase-interacting kinases (MAP kinase signal-integrating kinases). Front Biosci 2008; 13: 5359-5373.
10. Zhang Y, Li Y, Yang D. Phosphorylation of eIF-4E positively regulates formation of the eIF-4F translation initiation complex following DNA damage. Biochem Biophys Res Commun 2008; 367: 54-59.
11. Bianchini A, Loiarro M, Bielli P, Busà R, Paronetto MP, Loreni F et al. Phosphor-ylation of eIF4E supports protein synthesis, cell cycle progression and proliferation in prostate cancer cells. Carcinogenesis 2008; 29: 2279-2288.
12. Konicek BW, Stephens JR, McNulty AM, Robichaud N, Peery RB, Dumstorf CA et al. Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases. Cancer Res 2011; 71: 1849-1857.
13. Altman JK, Glaser H, Sassano A, Joshi S, Ueda T, Watanabe-Fukunaga R et al. Negative Regulatory Effects of Mnk Kinases in the Generation of Chemotherapy-Induced Antileukemic Responses. Mol Pharmacol 2010; 78: 778-784.
14. Wendel HG, Silva RL, Malina A, Mills JR, Zhu H, Ueda T et al. Dissecting eIF4E action in tumorigenesis. Genes Dev 2007; 21: 3232-3237.
15. Furic L, Rong L, Larsson O, Koumakpayi IH, Yoshida K, Brueschke A et al. eIF4E phopshorylation promotes tumorigenesis and is associated with prostate cancer progression. Proc Natl Acad Sci USA 2010; 107: 14134-14139.
16. Ueda T, Sasaki M, Elia AJ, Chio II, Hamada K, Fukunaga R et al. Combined deficiency for MAP kinase-interacting kinase 1 and 2 (Mnk1 and Mnk2) delays tumor development. Proc Natl Acad Sci USA 2010; 107: 13984-13990.
17. Graff JR, Konicek BW, Lynch RL, Dumstorf CA, Dowless MS, McNulty AM et al. eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survival. Cancer Res 2009; 69: 3866-3873.
18. Yoshizawa A, Fukuoka J, Shimizu S, Shilo K, Franks TJ, Hewitt SM et al. Over-expression of phopsho-eIF4E is associated with survival through AKT pathway in non-small-cell lung cancer. Clin Cancer Res 2010; 16: 240-248.
19. Chrestensen CA, Eschenroeder A, Ross WG, Ueda T, Watanabe-Fukunaga R, Fukunaga R et al. Loss of MNK function sensitizes fibroblasts to serum-withdrawal induced apoptosis. Genes Cells 2007; 12: 1133-1140.
20. Scheper GC, Parra JL, Wilson M, Van Kollenburg B, Vertegaal AC, Han ZG et al. The N and C termini of the splice variants of the human mitogen-activated protein kinase-interacting kinase Mnk2 determine activity and localization. Mol Cell Biol 2003; 23: 5692-5705.
21. Karni R, De Stanchina E, Lowe SW, Sinha R, Mu D, Krainer AR. The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol 2007; 14: 185-193.
22. David CJ, Chen M, Assanah M, Canoll P, Manley JL. HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 2010; 463: 364-368.
23. Bielli P, Busà R, Paronetto MP, Sette C. The RNA-binding protein Sam68 is a multifunctional player in human cancer. Endocr Relat Cancer 2011; 18: 91-102.
24. Assouline S, Culjkovic B, Cocolakis E, Rousseau C, Beslu N, Amri A et al. Molecular targeting of the oncogene eIF4E in AML: a proof-of principle clinical trial with ribavirin. Blood 2009; 114: 257-260.
25. Wolpin BM, Hezel AF, Abrams T, Blaszkowsky LS, Meyerhardt JA, Chan JA et al. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory meta-static pancreatic cancer. J Clin Oncol 2008; 27: 193-198.
26. Gonçalves V, Theisen P, Antunes O, Medeira A, Ramos JS, Jordan P et al. A missense mutation in the APC tumor suppressor gene disrupts an ASF/SF2 splicing enhancer motif and causes pathogenic skipping of exon 14. Mutat Res 2009; 662: 33-36.
27. Sanz DJ, Acedo A, Infante M, Durán M, Pérez-Cabornero L, Esteban-Carden?osa E et al. A high proportion of DNA variants of BRCA1 and BRCA2 is associated with aberrant splicing in breast/ovarian cancer patients. Clin Cancer Res 2010; 16: 1957-1967.
28. Hayes GM, Carrigan PE, Miller LJ. Serine-arginine protein kinase 1 overexpression is associated with tumorigenic imbalance in mitogen-activated protein kinase pathways in breast, colonic, and pancreatic carcinomas. Cancer Res 2007; 67: 2072-2080.
29. Hayes GM, Carrigan PE, Beck AM, Miller LJ. Targeting the RNA splicing machinery as a novel treatment strategy for pancreatic carcinoma. Cancer Res 2006; 66: 3819-3827.
30. Busà R, Paronetto MP, Farini D, Pierantozzi E, Botti F, Angelini DF et al. The RNA-binding protein Sam68 contributes to proliferation and survival of human prostate cancer cells. Oncogene 2007; 26: 4372-4382.
31. Pedrotti S, Bielli P, Paronetto MP, Ciccosanti F, Fimia GM, Stamm S et al. The splicing regulator Sam68 binds to a novel exonic splicing silencer and functions in SMN2 alternative splicing in spinal muscular atrophy. EMBO J 2010; 29: 1235-1247.
32. O'Loghlen A, Gonzalez VM, Pineiro D, Pérez-Morgado MI, Salinas M, Mart́in ME. Identification and molecular characterization of Mnk1b, a splice variant of human MAP kinase-interacting kinase Mnk1. Experimental Cell Res 2004; 299: 343-355.